Integrating Primary & Secondary Interventions for Cervical Cancer Prevention in Primary Care Settings
Primary Purpose
HPV-Related Carcinoma
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
brief negotiated mobile application
Sponsored by
About this trial
This is an interventional prevention trial for HPV-Related Carcinoma focused on measuring HPV vaccination, Cervical cancer screening, Primary care setting, Primary prevention of cervical cancer, Secondary prevention of cervical cancer, Mobile health information
Eligibility Criteria
Inclusion Criteria:
- AFG ages 30 years and older who receive primary care at the study sites.
- AFG consent to have cervical cancer screening status checked in Electronic Medical Record.
- AFG has a daughter between the ages of 11 to 17 who receive primary care at either
- Family Medicine or Pediatric and Adolescent primary care clinic at Boston Medical Center.
- AFG consent to have daughter's HPV vaccination status checked in Electronic Medical Record.
- AFG's daughter has neither initiated the HPV vaccine nor completed the three vaccine series
- AFG and daughter have the ability to read and write in English.
- AFG and daughter each have a cell phone with text messages capabilities.
Exclusion Criteria:
- The investigators will exclude based on the following criteria:
- AFG being seen for a sick visit.
- AFG has an adolescent daughter who is pregnant or is a mother.
- AFG has a daughter who has completed the three dose HPV vaccine series.
- AFG, in the opinion of the clinical staff, is cognitively impaired and unable to give informed consent and may not participate.
Sites / Locations
- Boston Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
single
Arm Description
single arm- behavioral educational intervention of a brief negotiated mobile application
Outcomes
Primary Outcome Measures
Number of participants who received the first dose and completed the vaccine series as measured electronic medical record review
The primary outcome of interest is receipt of the first dose and completion of the three or two-dose series of HPV vaccine by participants within 6 month of intervention, this will be evaluated by Electronic Measure Review. Unit of measure: Number of participants who received the first doses and who competed the total number of does based - recorded as percentage who receive the first dose, and completed the two or 3 doses.
Secondary Outcome Measures
Patient knowledge and provider-patient communication
The secondary outcomes are: (a) Change in knowledge of HPV, HPV vaccination, and cervical cancer screening as evaluated by pre/post intervention survey: unit of Measure: based on a 1-10 point scale, with 10 being the highest score;
provider communication about HPV vaccine
greater provider communication about HPV vaccine : Unit of measure- the number of participants who responded yes to provider communication about HPV vaccine
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03033550
Brief Title
Integrating Primary & Secondary Interventions for Cervical Cancer Prevention in Primary Care Settings
Official Title
A Single-arm Proof of Concept, Open Trial Clinical Study Investigating the Feasibility and Efficacy of Integrating Behavioral and Mobile Health Educational Interventions for Primary and Secondary Prevention in the Primary Care Setting
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
May 8, 2017 (Actual)
Primary Completion Date
May 21, 2018 (Actual)
Study Completion Date
June 8, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Boston Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether a mobile health educational intervention for Human PapillomaVirus (HPV) Vaccination promotion and cervical cancer screening in Primary Care settings is a feasible behavioral intervention to integrate as a primary and secondary cervical cancer prevention approach.Study Design: The investigators will conduct an open feasibility proof-of-concept trial using a single experimental group with all subjects receiving the behavioral intervention being studied.
Outcome measures. The primary outcome of interest is receipt of the first dose and completion of the three-dose series of HPV vaccine within 6 month of intervention, this will be evaluated by Electronic medical review review.
Detailed Description
Background: Nearly 80 million people in the US are infected with HPV and 14 million new cases are diagnosed annually. There is an increasing HPV prevalence among women through the young adult years. Although the body clears many HPV infections persistent infections can progress to cancer and other HPV-related diseases. Cervical cancer is the most common cancer caused by HPV.
Many of the HPV-associated cancers are preventable with a series of safe and effective HPV vaccines. To date, no state has attained the 80% target vaccination rate for HPV. Despite the proven benefits and safety of HPV vaccine, usage remains suboptimal (only 38% had completed the three-dose series) and lower than other recommended adolescent vaccines.
Objective/Hypothesis: Our short term objective is to increase HPV vaccine initiation and completion rates among all age-eligible adolescent girls for whom vaccine is not contraindicated; and explore and examine acceptability of providing HPV vaccination to female youth during her adult female guardian's (AFG) cervical cancer screening appointment.
The investigators hypothesize that a combined intervention which includes (1) a motivational web-based education aimed at AFGs and youth females in their Primary Care site; and (2) text message reminders and an informational web-link on HPV vaccine and cervical cancer screening will increase HPV vaccination rates among youth females and will increase cervical cancer screening rates among their respective AFGs.
The investigators propose the following Aim:
Specific Aim: Conduct a single-arm proof of concept, open trial clinical study investigating the feasibility and efficacy of integrating primary and secondary prevention model for HPV and cervical cancer: a mobile educational and automated electronic interactive messaging intervention that will remind AFG and youth females of scheduled and missed second and third HPV vaccination appointments, and deliver brief text and video educational messaging on HPV, HPV vaccine, and cervical cancer screening.
Study Design: The investigators will conduct an open feasibility proof-of-concept trial using a single experimental group with all subjects receiving the behavioral intervention being studied.
Outcome measures. The primary outcome of interest is receipt of the first dose and completion of the three-dose series of HPV vaccine within 6 month of intervention, this will be evaluated by Electronic medical review review.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HPV-Related Carcinoma
Keywords
HPV vaccination, Cervical cancer screening, Primary care setting, Primary prevention of cervical cancer, Secondary prevention of cervical cancer, Mobile health information
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
single
Arm Type
Experimental
Arm Description
single arm- behavioral educational intervention of a brief negotiated mobile application
Intervention Type
Behavioral
Intervention Name(s)
brief negotiated mobile application
Intervention Description
The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
Primary Outcome Measure Information:
Title
Number of participants who received the first dose and completed the vaccine series as measured electronic medical record review
Description
The primary outcome of interest is receipt of the first dose and completion of the three or two-dose series of HPV vaccine by participants within 6 month of intervention, this will be evaluated by Electronic Measure Review. Unit of measure: Number of participants who received the first doses and who competed the total number of does based - recorded as percentage who receive the first dose, and completed the two or 3 doses.
Time Frame
up to 6 months
Secondary Outcome Measure Information:
Title
Patient knowledge and provider-patient communication
Description
The secondary outcomes are: (a) Change in knowledge of HPV, HPV vaccination, and cervical cancer screening as evaluated by pre/post intervention survey: unit of Measure: based on a 1-10 point scale, with 10 being the highest score;
Time Frame
over 6 months
Title
provider communication about HPV vaccine
Description
greater provider communication about HPV vaccine : Unit of measure- the number of participants who responded yes to provider communication about HPV vaccine
Time Frame
through study completion, an average of 1 year
Other Pre-specified Outcome Measures:
Title
Cervical cancer screening rate
Description
Cervical cancer screening rate as evaluated by Electronic Medical Review review: Unit of Measure: Number of participants who has cervical cancer screening within the time guideline ( as measured and reported as percentage who screened within the pap smear guideline
Time Frame
through study completion, an average of 1 year
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
9 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
AFG ages 30 years and older who receive primary care at the study sites.
AFG consent to have cervical cancer screening status checked in Electronic Medical Record.
AFG has a daughter between the ages of 11 to 17 who receive primary care at either
Family Medicine or Pediatric and Adolescent primary care clinic at Boston Medical Center.
AFG consent to have daughter's HPV vaccination status checked in Electronic Medical Record.
AFG's daughter has neither initiated the HPV vaccine nor completed the three vaccine series
AFG and daughter have the ability to read and write in English.
AFG and daughter each have a cell phone with text messages capabilities.
Exclusion Criteria:
The investigators will exclude based on the following criteria:
AFG being seen for a sick visit.
AFG has an adolescent daughter who is pregnant or is a mother.
AFG has a daughter who has completed the three dose HPV vaccine series.
AFG, in the opinion of the clinical staff, is cognitively impaired and unable to give informed consent and may not participate.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Natalie Joseph, MD MPH
Organizational Affiliation
Boston Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Boston Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Integrating Primary & Secondary Interventions for Cervical Cancer Prevention in Primary Care Settings
We'll reach out to this number within 24 hrs